Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer.
Breast cancer
Immune checkpoint inhibitors
Predictive biomarkers
Journal
Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
17
03
2023
revised:
23
03
2023
accepted:
25
03
2023
medline:
16
6
2023
pubmed:
2
4
2023
entrez:
1
4
2023
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and now represent the mainstay of treatment for many tumor types, including triple-negative breast cancer and two agnostic registrations. However, despite impressive durable responses suggestive of an even curative potential in some cases, most patients receiving ICIs do not derive a substantial benefit, highlighting the need for more precise patient selection and stratification. The identification of predictive biomarkers of response to ICIs may play a pivotal role in optimizing the therapeutic use of such compounds. In this Review, we describe the current landscape of tissue and blood biomarkers that could serve as predictive factors for ICI treatment in breast cancer. The integration of these biomarkers in a "holistic" perspective aimed at developing comprehensive panels of multiple predictive factors will be a major step forward towards precision immune-oncology.
Identifiants
pubmed: 37003065
pii: S0960-9776(23)00431-9
doi: 10.1016/j.breast.2023.03.014
pmc: PMC10070181
pii:
doi:
Substances chimiques
Biomarkers
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
330-341Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.